Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 plus BP102 in advanced solid tumors
NCT04856774Phase 2Completed
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Jun 2021
- Primary completion
- Mar 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa in solid tumor (advanced stage), sponsored by Suzhou Suncadia Biopharmaceutical. Started Jun 2021; status: completed.
02
Drugs
retlirafusp alfa
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04856774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04856774.